Gilead liver disease med still delivers ahead of FDA verdict

Three months after spending $4.3 billion on CymaBay for its primary biliary cholangitis med, Gilead Sciences has presented a fresh slice of data.

Related Keywords

Merdad Parsey ,Gilead Sciences ,Cymabay Therapeutics ,Chief Medical Officer Merdad Parsey ,